PRS 060

Drug Profile

PRS 060

Alternative Names: AZD 1402; PRS-060

Latest Information Update: 04 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pieris Pharmaceuticals; University of Melbourne
  • Developer Pieris Pharmaceuticals
  • Class Antiasthmatics; Lipocalins
  • Mechanism of Action Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Asthma

Most Recent Events

  • 18 Jul 2018 Pieris Australia plans a phase I trial for Asthma, in July 2018 (NCT03574805)
  • 18 May 2018 Pharmacodynamics data from a preclinical study in Asthma presented at the 114th International Conference of the American Thoracic Society (ATS-2018)
  • 10 May 2018 Pieris Pharmaceuticals plans a follow-up study to the phase I trial for Asthma in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top